ImmunoPrecise Antibodies (NASDAQ:IPA) Shares Down 1%

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) fell 1% on Tuesday . The stock traded as low as $0.98 and last traded at $0.99. 43,161 shares traded hands during trading, a decline of 87% from the average session volume of 327,960 shares. The stock had previously closed at $1.00.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IPA. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of ImmunoPrecise Antibodies in a research note on Friday, March 15th. Benchmark reissued a “speculative buy” rating and set a $5.00 price target on shares of ImmunoPrecise Antibodies in a research note on Friday, March 15th.

ImmunoPrecise Antibodies Trading Down 2.2 %

The company has a quick ratio of 1.38, a current ratio of 1.66 and a debt-to-equity ratio of 0.25. The business’s fifty day moving average is $1.08 and its 200 day moving average is $1.42. The firm has a market capitalization of $25.22 million, a price-to-earnings ratio of -2.34 and a beta of 0.10.

Institutional Investors Weigh In On ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC grew its position in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 24.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,281,305 shares of the company’s stock after acquiring an additional 253,052 shares during the period. Ingalls & Snyder LLC owned about 4.87% of ImmunoPrecise Antibodies worth $2,191,000 at the end of the most recent quarter. Institutional investors own 6.70% of the company’s stock.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.